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Background: There are limited published data on the outcomes of
infants starting antiretroviral therapy (ART) in routine care in
Southern Africa. This study aimed to examine the baseline character-
istics and outcomes of infants initiating ART.
Methods: We analyzed prospectively collected cohort data from
routine ART initiation in infants from 11 cohorts contributing to the
International Epidemiologic Database to Evaluate AIDS in Southern
Africa. We included ART-naive HIV-infected infants aged ,12
months initiating $3 antiretroviral drugs between 2004 and 2012.
Kaplan–Meier estimates were calculated for mortality, loss to
follow-up (LTFU), transfer out, and virological suppression. We
used Cox proportional hazard models stratiﬁed by cohort to
determine baseline characteristics associated with outcomes mortal-
ity and virological suppression.
Results: The median (interquartile range) age at ART initiation of
4945 infants was 5.9 months (3.7–8.7) with follow-up of 11.2
months (2.8–20.0). At ART initiation, 77% had WHO clinical stage
3 or 4 disease and 87% were severely immunosuppressed. Three-
year mortality probability was 16% and LTFU 29%. Severe
immunosuppression, WHO stage 3 or 4, anemia, being severely
underweight, and initiation of treatment before 2010 were associated
with higher mortality. At 12 months after ART initiation, 17% of
infants were severely immunosuppressed and the probability of
attaining virological suppression was 56%.
Conclusions: Most infants initiating ART in Southern Africa had
severe disease with high probability of LTFU and mortality on ART.
Although the majority of infants remaining in care showed immune
recovery and virological suppression, these responses were suboptimal.
Key Words: infants, antiretroviral therapy, outcomes, Southern
Africa
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INTRODUCTION
Despite advances in Prevention of Mother-to-Child
Transmission (PMTCT) programs, including possible reduc-
tion of vertical transmission to as low as 1%,1 900 HIV-
infected infants were born daily in 2011, the vast majority in
sub-Saharan Africa.2 Infants differ from older children and
adults with respect to rapid physical growth (especially of
their developing brain), establishment of a functioning immune
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system and rapidly changing physiology.3–5 Furthermore,
infants infected with HIV experience increased vulnerability
to the multiple insults of the virus and its complications
including accelerated disease progression and increased risk of
morbidity and mortality.6–12 These worsened outcomes,
together with age-speciﬁc diagnostic treatment and monitoring
challenges related to pediatric HIV policy, drugs, and testing,
make infants a high-risk population.5,8,13–15
There has been much progress in infant HIV care in
recent years: 2008 international guidelines recommended
initiation of ART in all infants younger than 12 months,
regardless of immunological and clinical status.16 Subse-
quently, the 2010 and 2013 guidelines were amended to
provide ART for all children younger than 2 years and
younger than 5 years, respectively.17,18 These changes were
largely informed by studies such as the Children with Human
Immune Deﬁciency Virus Early Antiretroviral Therapy Trial
(CHER). This trial, conducted in South Africa (SA), quanti-
ﬁed the beneﬁts of early ART initiation before 12 weeks of
age, demonstrating a 76% reduction in mortality and 75%
reduction in HIV progression compared with deferring ART
until World Health Organization (WHO) 2006 treatment
initiation criteria were met.19,20
However, the features of this trial and its participants
differ considerably from the context of the resource-scarce
routine care setting of Southern Africa.5,14,15,20–23 For exam-
ple, the average age at commencement of ART was 7 weeks,
there was availability of appropriate laboratory testing, and
drug regimens including protease inhibitors, minimal loss to
follow-up (LTFU), and those with comorbid conditions or
severe immunosuppression were speciﬁcally excluded.
There are few studies on the outcomes of infants
starting ART in routine care in resource-scarce settings
including mostly only small numbers of infants starting
therapy since the implementation of the WHO 2008 recom-
mendation for immediate ART initiation in infants. Using
data merged from cohorts in the International Epidemiologic
Database to Evaluate AIDS in Southern Africa (IeDEA-SA),
our study aimed to describe baseline characteristics of infants
starting ﬁrst-line ART in routine care within Southern Africa,
their treatment outcomes, including clinical, immunological,
and virological responses, and to identify determinants for
these outcomes.
METHODS
We conducted an analysis of prospectively collected
cohort data of infants initiating ART in routine care between
January 2004 and December 2012 at sites contributing to the
IeDEA-SA collaboration.24 Infants were deﬁned as less than
12 months of age at ART initiation. IeDEA-SA data are
collated on site by cohort investigators through routine
clinical follow-up of infants as part of the standard treatment
and monitoring of HIV.19,25–27 Anonymized data are then
transferred to the central IeDEA-SA Data Centre using a Data
Transfer Protocol.
We included 11 cohorts from SA, Zimbabwe, Malawi,
and Zambia. Cohort inclusion required initiation of infants
on ART both before and after January 1, 2010, so as to
ensure that each cohort included a portion of infants initiated
after the release of the WHO 2010 guidelines for early
initiation.27 HIV-infected (recorded PCR diagnosis or pre-
sumptive diagnosis), ART-naive (except for PMTCT expo-
sure) infants with a recorded date of initiation of at least 3
antiretroviral drugs before the age of 12 months were
eligible for inclusion. Participants with missing data for
date of ART initiation, age, and gender were excluded as
were infants identiﬁed as being virologically suppressed
(HIV-RNA ,400 copies/mL) at ART initiation due to
possible non-naivety to ART. Eligibility for ART initiation
was cohort speciﬁc and reﬂected the country guidelines at
the time.
Each cohort has institutional ethical approval for contri-
bution of data to IeDEA-SA. Ethical approval for the database
and this analysis was obtained from the Human Research
Ethics Committee of the University of Cape Town, SA.
Characteristics of infants at ART initiation included
demographic details, anthropometric measures, hemoglobin
(Hb), clinical (WHO clinical staging),28 immunological, and
virological markers of disease severity, and information
about medicines administered including PMTCT drugs.
These characteristics are presented overall and according
to time period of initiation using medians and proportions
and compared using Wilcoxon rank-sum and x2 tests,
respectively.
Measurements from the closest date to ART initiation
within an interval of 6 months before and 1 week after
initiation were used for laboratory baseline characteristics and
3 months before, up to the day of initiation for anthropometric
characteristics. Age at ART initiation was categorized as ,3
months, 3 to ,6, and 6 to ,12 months. Severe anemia was
deﬁned using the Division of AIDS (DAIDS) guidelines29:
Hb ,10 g/dL (age: #21 days); ,8 g/dL (age: 22–35 days);
,7 g/dL (age: 36–56 days); and ,7.5 g/dL (age: $57 days).
Weight and height measures were converted to age- and
gender-speciﬁc z-scores [weight-for-age z-score (WAZ),
height-for-age z-score (HAZ), and weight-for-height (WFHZ)
using the 2007 WHO growth reference standards].30 WAZ
and HAZ were further categorized as ,23, 23 to 22, and
.22. Severe immunosuppression was deﬁned where the
lowest of the CD4 absolute cell count or percentage met
classiﬁcation as per WHO criteria.28 Virological suppression
was deﬁned as the ﬁrst recorded viral load ,400 copies per
milliliter. Year of initiation was dichotomized as before or
after ﬁrst of January 2010 to reﬂect the 2010 WHO changes to
guidelines for ART initiation.27
Outcomes were death, transfer out (TFO), LTFU, and
virological suppression. LTFU was deﬁned as the last recorded
visit.9 months before cohort database closure with the date of
LTFU being the date of the last visit. Response variables
included CD4 absolute cell count and percentage, viral load,
and anthropometric measures (WAZ and HAZ).
Statistical Methods
Anthropometric, immunological, and hemoglobin re-
sponses over time on ART were examined in infants who
remained in care for at least 12 months. This was to
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approximate a true change in averages by minimizing the effect
of loss (through death, LTFU) of the sicker infants on these
averages. We used the Kaplan–Meier method to estimate the
probability of death, TFO, LTFU, and virological suppression.
Because of the interdependence of death, TFO, and LTFU, we
also conducted Competing Risk analysis to determine the
Cumulative Incidence Functions for these outcomes. We used
Cox proportional hazard models stratiﬁed by cohort to
determine baseline characteristics associated with mortality.
Because of the high levels of missing virological data from
cohorts outside SA, a separate model including estimates for
baseline virological characteristics within SA cohorts was
analyzed. We used Cox proportional hazard models stratiﬁed
by cohort to determine baseline characteristics associated with
time to virological suppression in infants from SA cohorts who
had a baseline viral load and at least 1 follow-up viral load
measurement recorded.
Missing baseline data for CD4 count and percent, Hb,
WAZ, HAZ, and WHO stage were modeled using multiple
imputation. The imputation model, with the assumption of data
missing at random, included all baseline characteristics, includ-
ing cohort, age and year of initiation, outcomes of mortality,
LTFU and TFO, and follow-up time. Five imputation sets were
generated and reported estimates representing pooled imputed
data estimates were calculated using Rubin Rules.31 Independent
variables for inclusion in the models were selected a priori and
are complemented by a postimputation model selection method
using model averaging based variable importance (VI) and an
estimate weight according to both frequency and strength of
association in the augmented data sets.32,33 All statistical analysis
was done using STATA 12.0 with multiple imputation done
using ICE.34
RESULTS
The median [interquartile range (IQR)] age at ART
initiation of 4945 infants was 5.9 months (3.7–8.7) with
median follow-up of 11.2 months (IQR, 2.8–20.0). Among
the 11 cohorts included representing all levels of care, 8 SA
sites contributed 3473 (70%) of infants. About a quarter
(26%) of infants initiated ART from 2010 onward.
Baseline Characteristics
At ART initiation, 77% of infants were classiﬁed as
WHO clinical stage 3 or 4 and 87% were severely immuno-
suppressed (Table 1). The distribution of these characteristics
by age group is summarized in Table S1 (see Supplemental
Digital Content, http://links.lww.com/QAI/A689). Approxi-
mately 60% of infants were either moderately or severely
underweight and approximately 60% were either moderately
or severely stunted at initiation. The median viral load was
5.99 log10 copies per milliliter (IQR, 5.41–6.45). Infants
initiating ART from the start of 2010 were generally younger
with less severe illness than those initiating before 2010
(Table 1). Missing baseline data were seen in all anthropo-
metric and laboratory measures, especially virological data
(Tables 1 and 2).
Mortality and Programmatic Outcomes
Mortality was highest in the few months after ART
initiation with 6- and 12-month cumulative probabilities of
10.1% [95% conﬁdence interval (CI): 9.3 to 11.1] and 13.2%
(95% CI: 12.1 to 14.3), respectively (Fig. 1A). LTFU was
considerable in the ﬁrst year with 6 and 12 months
probabilities of 13.7% (95% CI: 12.7 to 14.7) and 18.8%
TABLE 1. Baseline Characteristics of Infants Initiating ART, 2004–2012: Demographic, Clinical, and Laboratory Characteristics at
Initiation
Characteristics N = 4945, N (%) Overall* 2004–2009 2010–2012 P
Age, mo, median (IQR) 4945 (100) 5.9 (3.7 to 8.7) 6.1 (3.8 to 8.9) 5.4 (3.4 to 8.4) 0.0000
Female, n (%) 4945 (100) 2546 (51.5) 1845 (50.7) 701 (53.7) 0.0603
WHO stage 3 or 4, n (%) 4347 (87.9) 3327 (76.5) 2605 (81.2) 722 (63.4) 0.0000
Absolute CD4, median (IQR) 3417 (69.1) 765 (347 to 1334) 724 (324 to 1274) 887 (440 to 1535) 0.0000
CD4 percentage, median (IQR) 3244 (65.6) 18.5 (12 to 26) 18 (11.5 to 24.9) 20.7 (13.6 to 28.4) 0.0000
Severe immunosuppression (WHO 2006), n (%) 3514 (71.1) 3063 (87.2) 2336 (89.2) 727 (81.3) 0.0000
Viral load $1,000,000, n (%) 2042 (41.3) 1012 (49.6) 815 (49.5) 197 (49.6) 0.9777
Severe anemia (DAIDS 2009), n (%) 2813 (56.7) 248 (8.8) 176 (8.7) 72 (9.0) 0.8182
WAZ, median (IQR) 3795 (76.7) 22.5 (23.9 to 21.2) 22.7 (24.1 to 21.3) 22.1 (23.5 to 20.8) 0.0000
WAZ category, n (%)
.22 1523 (40.1) 1.037 (37.1) 486 (48.3) 0.0000
#22 to .23 686 (18.1) 510 (18.3) 176 (17.5) 0.5762
#23 1586 (41.8) 1242 (44.5) 344 (34.2) 0.0000
HAZ, median (IQR) 2919 (59.0) 22.5 (23.9 to 21.1) 22.6 (24.0 to 21.3) 22.2 (23.5 to 20.8) 0.0000
HAZ category, n (%)
22 1177 (40.3) 844 (38.6) 333 (45.5) 0.0010
#22 to .23 538 (18.4) 392 (17.9) 146 (19.9) 0.2222
#23 1204 (41.3) 951 (43.5) 253 (34.6) 0.0000
*Proportions represent proportion of nonmissing (N) observations.
N, number of nonmissing observations.
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(95% CI: 17.6 to 20.1), respectively (Fig. 1A). TFO from
a higher level of care to another facility occurred throughout
follow-up with the 36-month probability being 34.2% (95%
CI: 32.3 to 36.1) (Fig. 1A). The cumulative incidence
functions from a competing risk analysis provided a 12-
month probability of mortality (competing with LTFU and
TFO) of 11.3% (95% CI: 10.4 to 12.2) (Fig. 1B). The
corresponding probabilities of being alive and in care at 6 and
12 months were 71.5% (95% CI: 70.2 to 72.7) and 59.6%
(95% CI: 58.2 to 61.0), respectively. Unadjusted comparison
of outcomes according to time period of initiation suggested
decreased mortality and a trend to lower LTFU in those
initiating ART from the start of 2010 (Log-rank test P =
0.0005 and 0.0576, respectively) (Figs. 1C, D).
Severe immunosuppression [adjusted hazard ratio
(aHR), 2.19; 95% CI: 1.44 to 3.33], WHO stage 3 or 4
(aHR, 1.36; 95% CI: 1.04 to 1.78), lower WAZ, and initiation
of ART from the start of 2010 were found to be independently
associated with mortality (Table 3). Compared with having
a WAZ of .22 those infants with WAZ ,23 at baseline
had a 2.34-fold (aHR, 2.34; 95% CI: 1.78 to 2.80) increased
risk of death. After adjusting for disease severity at baseline,
infants initiating ART from the start of 2010 had a reduced
risk of death compared with those initiated before 2010 (aHR,
0.75; 95% CI: 0.59 to 0.94). There was no evidence of an
effect of infant age group on mortality. Overall estimates from
the imputed data sets provided similar estimates to complete
case analysis (see Table S2, Supplemental Digital Content,
http://links.lww.com/QAI/A689 demonstrating imputed and
complete case survival analyses). In an analysis restricted to
infants from SA cohorts, there was no association between
baseline viral load category and death after adjustment for other
disease severity characteristics at baseline (see Table S2,
Supplemental Digital Content, http://links.lww.com/QAI/A689
demonstrating an analysis of the association of baseline viral
load category and the outcome mortality in a subset of
SA infants).
Responses to ART
Anthropometric, immunological, and hemoglobin re-
sponses to ART were examined for infants remaining in care
for at least 12 months. Weight-for-age showed rapid improve-
ment in the ﬁrst 6 months of therapy with an increase from
a median WAZ of 22.40 to 20.97 (see Figure S1, Supple-
mental Digital Content, http://links.lww.com/QAI/A689 dem-
onstrating growth response on ART over time for infants
remaining in care for at least 1 year). Height-for-age showed
a slower increase reaching a median HAZ of 21.97 from
a baseline of 22.34 after 1 year on ART.
Absolute CD4 count showed a rapid increase in the ﬁrst
year after initiation with a 12-month median CD4 cell count
of 1573 cells per milliliter almost double that at baseline (Fig.
2A). As expected, CD4 percentages, adjusting more appro-
priately for age-related immunological changes, showed
a similar initial trend of improvement that was sustained,
only plateauing at 36 months (Fig. 2B). These combined effects
can be seen in the change in the proportion of infants meeting
the WHO criteria for severe immunosuppression with a reduc-
tion from 87% (95% CI: 86 to 89) at baseline to 17% (95% CI:
15 to 18) at 12 months and 3% (95% CI: 2 to 4) at 36 months.
Median (IQR) hemoglobin increased from a baseline of 9.7 to
11 g/dL (10.2–12.0) at 6 months (see Figure S2, Supplemental
Digital Content, http://links.lww.com/QAI/A689 demonstrating
the change in median hemoglobin over time for infants
remaining in care for over 12 months).
Among a subset of SA infants with at least baseline and
one other viral load measurement (n = 1364), the probabilities of
virological suppression at 6 and 12 months were 28.1% (95%
CI: 25.6 to 30.7) and 56.1% (95% CI: 53.2 to 59.1), respectively
(Fig. 2C). A viral load of $1 million copies per milliliter at
ART start was the only independent predictor of failure to
suppress (aHR, 0.78; 95% CI: 0.68 to 0.89) (see Table S3,
Supplemental Digital Content, http://links.lww.com/QAI/A689
demonstrating imputed and complete case analyses of virolog-
ical suppression in this subset of infants).
DISCUSSION
In this study, we found that infants initiating ART in
Southern Africa between 2004 and 2012 were older with
a high prevalence of severe baseline disease. The improve-
ment in these characteristics from the start of 2010 onward
reﬂects WHO guideline changes: a proportion of infants
initiating ART in the latter period had no severe disease
characteristics. Despite considerable early responses to ART
and a reduction in the prevalence of severe disease character-
istics, infants remaining in care experienced suboptimal
immunological, anthropometric, and virological responses.
Furthermore, mortality, particularly in the initial stage after
ART initiation, was high and LTFU was substantial through-
out the observation period. Initiation of ART before 2010 was
an independent predictor of mortality. Similar LTFU before
2010 and from the start of 2010 suggests that the apparent
TABLE 2. Baseline Characteristics of Infants Initiating ART,
2004–2012: Drug Regimens and PMTCT Exposure
N (%)
Overall,* N
(%)
First-line regimen,
n (%)
D4T + 3TC + lopinavir/
ritonavir
4653 (94.1) 2068 (44.4)
D4T + 3TC + nevirapine 971 (20.9)
ABC + 3TC + lopinavir/
ritonavir
598 (12.9)
AZT + 3TC + nevirapine 343 (7.4)
AZT + 3TC + lopinavir/
ritonavir
286 (6.2)
Other 387 (8.3)
Third ART drug,
n (%)
lopinavir/ritonavir 4659 (94.2) 2957 (63.5)
ritonavir 214 (4.6)
nevirapine 1399 (30.0)
efavirenz 89 (1.9)
PMTCT exposed,
n (%)
1637 (33.1) 948 (57.9)
*Proportions represent proportion of nonmissing (N) observations.
3TC, lamivudine; ABC, abacavir; AZT, zidovudine; D4T, stavudine; N, number of
nonmissing observations.
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decreased mortality was unlikely to be due to under-
ascertainment of mortality in the later period.
The CHER trial showed the beneﬁts of early ART in
a cohort of very young infants with complete absence of
severe immunosuppression at baseline.20 The low likelihood
of fully achieving these beneﬁts in the SA routine care setting
due to suboptimal coverage of early infant HIV diagnosis was
highlighted by Johnson et al35 in a model-based analysis
examining the effect of early ART. Our study has conﬁrmed
through observation what this analysis suggested—within the
context of delayed initiation infant ART outcomes are
suboptimal. The predominance of severe baseline disease
and failure to attain normal immunological, anthropometric,
and virological measures, as well as high mortality and LTFU
are cause for considerable concern. Furthermore, with an
estimated 45% of in utero-infected and 22% of intrapartum-
infected infants dying or lost to follow-up by 14 weeks of
age,36 our concern is exacerbated by the uncaptured pre-ART
losses seen with delayed initiation.
This study has described improvements in delay in
ART initiation over time, a trend seen when comparing earlier
observational studies from sub-Saharan Africa to more recent
studies. These improvements include reductions in age at
initiation,21,37 baseline disease severity, and mortality.9,21 Our
results are also comparable with more recent studies of
immunological38,39 and anthropometric responses21,40 as well
as mortality41 in infants on ART within sub-Saharan Africa.
However, our ﬁndings regarding virological suppression
differ considerably from previous studies such as Kay
et al42 who described a 45% 12 month probability of
virological suppression (deﬁned as 2 consecutive viral load
,400 copies/mL) and Tukei et al21 who described a 72% 12
month probability of virological suppression in a cohort of
infants with at least 6 months of ART. These differences are
largely due to population and treatment program differences
in these studies. The low probability of virological suppres-
sion seen in our study may be due speciﬁcally to the use of
suboptimal regimens such as regimens using nevirapine or
ritonavir alone as “third drugs” with known poorer virological
efﬁcacy.43,44 Another possible cause is cotreatment for
tuberculosis, complicating ART regimen choice and, in some
cases, reducing virological efﬁcacy.45
We found improved mortality from the start of 2010
(when early initiation was implemented on a national scale)
FIGURE 1. Survival analysis for outcomes mortality, loss to follow-up, and transfer out in infants initiating ART in Southern Africa
2004–2012. A, Kaplan–Meier estimates for outcomes of infants initiating ART in Southern Africa. B, Competing risk analysis for
outcomes of infants initiating ART in Southern Africa. C, Kaplan–Meier estimates for mortality by time period of initiation. D,
Kaplan–Meier estimates for loss to follow-up by time period of initiation.
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over and above that expected from the improvements in age
and baseline characteristics. This indicates a possible role of
subtle changes in baseline disease severity and programmatic
improvements on the outcomes observed, suggesting that the
implementation of guidelines for early infant initiation may
have resulted in an improvement in mortality through a greater
urgency and attention toward infant HIV diagnosis and ART
initiation.
To our knowledge, this is the largest study of infant
ART outcomes in sub-Saharan Africa to date. The study
includes HIV-infected infants initiating ART from several
Southern African routine care cohorts representing all levels
of health care. In addition, the data cover a period of
considerable guideline changes, strengthening the study.
The use of multiple imputation to account for missing
baseline data has prevented the bias associated with complete
case analysis.46,47 The high proportion of missing virological
data, due to unavailability of virological measures outside SA,
meant virological predictors and outcomes could only be
assessed for South African cohorts.
The observed median age at ART initiation was
considerably beyond 3 months of age. While this is the
reality of routine care, it is likely to have resulted in some
survival bias. This survival effect, greater in older infants
having survived longer, would reduce any potential beneﬁt of
starting ART at a younger age and may explain the lack of
age effect on outcomes. In addition, lack of data on
comorbidities, infant feeding practices, PMTCT, cotrimox-
azole prophylaxis, and socioeconomic factors may have
resulted in residual confounding. Furthermore, associations
between regimen and outcomes were not examined due to
a near perfect correlation with cohort/country of origin. There
may also be under-ascertainment of mortality in view of the
high proportion of infants LTFU. The IeDEA-SA database
requires electronic data capturing by cohorts; hence, the
results may not be representative of all cohorts providing
routine care in Southern Africa.
Recommendations
Ongoing attention to the initiation and continued manage-
ment of ART in infants is required to optimize infant HIV care
and outcomes. This needs to include considerable effort toward
early diagnosis, successful referral, and retention in care. The
continued vulnerability of infants on ART could be reduced
through efforts to achieve the standards set by the trials on whose
evidence guidelines for early initiation were based. Research is
therefore necessary to identify how to overcome barriers to early
initiation and optimal care of HIV-infected infants, including
issues of PMTCT linkage, birth testing, infant ART initiation,
optimization and maintenance, and a reduction of LTFU.
CONCLUSIONS
In a large cohort of HIV-infected infants in routine care
in Southern Africa, we observed improvements in both
disease severity characteristics at ART initiation and sub-
sequent outcomes on ART. However, even after 2010, ART
initiation was delayed with severe baseline illness and
persistent vulnerability of infants despite receiving ART.
TABLE 3. Survival Analysis of Imputed Data: Cox Regression for Predictors of Mortality Stratified by Cohort
Variable
Univariate Multivariate* Model Selection †
HR P 95% CI HR P 95% CI HR 95% CI VI
Female gender 0.97 0.716 0.83 to 1.14 — — — — — 0.31
Age at initiation, mo
0–2 Reference Reference Reference
3–5 0.90 0.417 0.71 to 1.15 0.87 0.268 0.68 to 1.11 — — 0.22
6–11 0.98 0.898 0.78 to 1.25 0.84 0.161 0.66 to 1.07 — — —
Nonsevere immune suppression (WHO 2006) Reference Reference Reference
Severe immune suppression (WHO 2006) 2.51 0.000 1.66 to 3.79 2.19 0.000 1.44 to 3.33 2.15 1.42 to 3.27 1
WHO stage 1 or 2 Reference Reference Reference
WHO stage 3 or 4 1.89 0.000 1.47 to 2.45 1.36 0.023 1.04 to 1.78 1.35 1.04 to 1.77 0.87
Mild or moderate anemia (DAIDS 2009) Reference Reference Reference
Severe anemia (DAIDS 2009) 1.57 0.003 1.18 to 2.10 1.34 0.062 0.98 to 1.82 1.29 0.82 to 2.05 0.79
WAZ category
Greater than 22 Reference Reference Reference
22 to 23 1.40 0.015 1.07 to 1.84 1.29 0.063 0.99 to 1.71 1.29 0.99 to 1.71 1
Lesser than 23 2.55 0.000 2.04 to 3.19 2.23 0.000 1.78 to 2.80 2.22 1.78 to 2.79 —
ART initiation before 2010 Reference Reference Reference
ART initiated from the start of 2010 0.65 0.000 0.52 to 0.83 0.75 0.015 0.59 to 0.94 0.75 0.59 to 0.95 0.88
‡Viral load #1 million copies/mL Reference Reference Reference
‡Viral load .1 million copies/mL 1.30 0.045 1.01 to 1.68 1.17 0.267 0.88 to 1.56 1.14 0.79 to 1.62 0.56
*Adjusted for age, weight-for-age category, severe immunosuppression, WHO stage 3 or 4, severe anemia, and initiation from the start of 2010.
†Using AIC and model averaging.
‡Modeled on a subset of infants from South African cohorts, adjusted for variables as above.
CI, conﬁdence interval; DAIDS, Division of AIDS; HR, hazard ratio; VI, variable importance; WAZ, weight-for-age z-score; WHO, World Health Organization.
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